vxa-cov2-1
Vaccineexperimental
Clinical trial activity
3 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Sep 21, 2020 (NCT04563702)
Timeline
Indications
Studied for
Mechanism of action
- SARS-CoV-2Immunity, active
SARS-CoV-2 immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06672055 | Phase 2 | Oct 8, 2024 | Vaxart |
| NCT05067933 | Phase 2 | Oct 31, 2021 | Vaxart |
| NCT04563702 | Phase 1 | Sep 21, 2020 | Vaxart |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Vaxart | For profit | 3 | 3 | 2 | 2020 |
1 organizations
Page 1 / 1